Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
08:30am, Monday, 22'nd Sep 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearanc
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
01:35pm, Friday, 19'th Sep 2025
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ: TEM) breached their
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
09:21am, Tuesday, 16'th Sep 2025
Tempus AI secures FDA clearance for its updated Pixel cardiac imaging platform, boosting radiology precision and efficiency.
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
08:00am, Monday, 15'th Sep 2025
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15,
Tempus AI stock is cheap as Murrey Math Lines points to more gains
01:09pm, Friday, 12'th Sep 2025
Tempus AI stock price surged to a record high on Wednesday after the healthcare-focused artificial intelligence company announced a major breakthrough from the Food and Drug Administration (FDA). It j
Tempus AI: Is TEM Stock A 10x Growth Story?
10:05am, Friday, 12'th Sep 2025
Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly acc
Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar?
09:46am, Friday, 12'th Sep 2025
Tempus (TEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Tempus AI Stock Soared Nearly 14% Higher Today
06:26pm, Thursday, 11'th Sep 2025
The stock of healthcare-focused artificial intelligence company Tempus AI (TEM 13.26%) was the cure for aching portfolios on Thursday. The company's share price ballooned by almost 14% on the back of
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging
01:58pm, Thursday, 11'th Sep 2025
On Thursday, Tempus AI, Inc. TEM received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform.
Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move
11:09am, Thursday, 11'th Sep 2025
Tempus AI stock jumped into a profit-taking zone Thursday after the FDA cleared its updated cardiac-imaging platform, Tempus Pixel.
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
09:36am, Thursday, 11'th Sep 2025
Tempus AI's PurIST test secures clinical validation, helping personalize treatment choices for advanced pancreatic cancer patients.
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
08:30am, Thursday, 11'th Sep 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. F
Why Are Stock Market Investors Talking About TempusAI Stock?
11:05am, Wednesday, 10'th Sep 2025
TempusAI (TEM -0.01%) is generating excellent revenue growth, and that has stock market investors excited.
Stock Market Investors Want to Know: What's Going on With TempusAI Stock?
10:43am, Wednesday, 10'th Sep 2025
The stock price is soaring, and investors are curious about the cause of the increase.
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
09:45am, Tuesday, 09'th Sep 2025
Tempus AI TEM posted robust second-quarter results and raised the sales guidance for 2025 for the second time within six months. Full-year revenues are now expected to be approximately $1.26 billion (
